Sign in Subscribe
Clinical trials

Breakthrough in Prostate Cancer Treatment: New Radiopharmaceutical Composition Shows Promise

Strategic Insights

— 2 min read

A newly developed radiopharmaceutical composition, created by inventors Jalomaki and Seppanen, has shown significant promise in treating prostate cancer with lower rates of toxicity. The composition, which targets prostate-specific membrane antigen (PSMA), has been designed to provide a safer and more effective treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC).

The composition, named 225 Actinium-PSMA-I&T, includes actinium, ascorbic acid, and ethanol, and has been shown to result in low toxicity profiles, providing better effects and fewer adverse effects than monoclonal antibody treatments and other comparable third-line treatments. The inventors claim that the composition can lead to a prostate-specific antigen decline of more than 50% upon administration to a subject in need.

According to the patent application, the composition has several advantages over existing treatments, including lower rates of haematotoxicity and nephrotoxicity. The claims supplied by the inventors outline the composition's formulation and properties, including the radioactivity concentration, pH range, and concentration of ascorbic acid and ethanol.

This breakthrough could potentially offer a new hope for patients with mCRPC who have not responded to existing treatments. With further research and development, 225 Actinium-PSMA-I&T may become a valuable addition to the arsenal of treatments for this devastating disease.

Key Takeaways:

  • A new radiopharmaceutical composition, 225 Actinium-PSMA-I&T, has been developed to treat prostate cancer with lower rates of toxicity.
  • The composition targets prostate-specific membrane antigen (PSMA) and has been shown to result in low toxicity profiles.
  • The composition includes actinium, ascorbic acid, and ethanol, and has been designed to provide a safer and more effective treatment option for patients with mCRPC.
  • The inventors claim that the composition can lead to a prostate-specific antigen decline of more than 50% upon administration to a subject in need.
  • The composition has several advantages over existing treatments, including lower rates of haematotoxicity and nephrotoxicity.
  • The claims supplied by the inventors outline the composition's formulation and properties, including the radioactivity concentration, pH range, and concentration of ascorbic acid and ethanol.

Statistics:

  • 899,000 new cases and 258,000 PC deaths worldwide in 2008 (Source: Jalomaki, Jarno; Seppanen, Salla. Radiopharmaceutical Compositions For Low Toxicity Actinium In Targeted Radionuclide Therapy. U.S. Patent Application Number 20250303004, filed August 3, 2022 and posted October 2, 2025)
  • 47 patients treated with 177 Lu-PSMA mAb J591 experienced grade 4 thrombocytopenia in 46.8% (Source: Jalomaki, Jarno; Seppanen, Salla. Radiopharmaceutical Compositions For Low Toxicity Actinium In Targeted Radionuclide Therapy. U.S. Patent Application Number 20250303004, filed August 3, 2022 and posted October 2, 2025)
  • 25.5% of patients experienced grade 4 neutropenia in clinical trials using 177 Lu-PSMA mAb J591 (Source: Jalomaki, Jarno; Seppanen, Salla. Radiopharmaceutical Compositions For Low Toxicity Actinium In Targeted Radionuclide Therapy. U.S. Patent Application Number 20250303004, filed August 3, 2022 and posted October 2, 2025)
  • 225 Actinium-PSMA-I&T composition has a radioactivity concentration of about 0.3 MBq to about 1.4 MBq per ml (Source: Jalomaki, Jarno; Seppanen, Salla. Radiopharmaceutical Compositions For Low Toxicity Actinium In Targeted Radionuclide Therapy. U.S. Patent Application Number 20250303004, filed August 3, 2022 and posted October 2, 2025)
  • 225 Actinium-PSMA-I&T composition has a pH of between 5 and 8 (Source: Jalomaki, Jarno; Seppanen, Salla. Radiopharmaceutical Compositions For Low Toxicity Actinium In Targeted Radionuclide Therapy. U.S. Patent Application Number 20250303004, filed August 3, 2022 and posted October 2, 2025)

Sources:

  • Jalomaki, Jarno; Seppanen, Salla. Radiopharmaceutical Compositions For Low Toxicity Actinium In Targeted Radionuclide Therapy. U.S. Patent Application Number 20250303004, filed August 3, 2022 and posted October 2, 2025.

Read more